T
Turid Aas
Researcher at Haukeland University Hospital
Publications - 64
Citations - 15205
Turid Aas is an academic researcher from Haukeland University Hospital. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 22, co-authored 56 publications receiving 14058 citations. Previous affiliations of Turid Aas include University of Bergen.
Papers
More filters
Journal ArticleDOI
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Ranjan Chrisanthar,Ranjan Chrisanthar,Stian Knappskog,Stian Knappskog,Erik Løkkevik,Gun Anker,Gun Anker,Bjørn Østenstad,Steinar Lundgren,Terje Risberg,Ingvil Mjaaland,Gudbrand Skjønsberg,Turid Aas,Ellen Schlichting,Hans E. Fjøsne,Arne Nysted,Johan R. Lillehaug,Per Eystein Lønning,Per Eystein Lønning +18 more
TL;DR: The predictive and prognostic value of TP53 and CHEK2 mutation status together with MDM2 SNP309 genotype in stage III breast cancer patients receiving paclitaxel or epirubicin monotherapy was explored.
Journal ArticleDOI
Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status.
Per Eystein Lønning,Hildegunn Helle,Hildegunn Helle,Nhat K. Duong,Nhat K. Duong,Dagfinn Ekse,Dagfinn Ekse,Turid Aas,Jürgen Geisler,Jürgen Geisler +9 more
TL;DR: Considering malignant tumours, intratumour E(1) levels were reduced in cancer tissue obtained from pre- as well as postmenopausal women independent of tumour ER status, suggesting intratumours aromatization to be of minor importance.
Journal ArticleDOI
Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics
TL;DR: Women treated with BCT have significantly better breast cancer-specific survival and a lower risk of dying from breast cancer compared to women treated with mastectomy, independent of detection mode, prognostic and predictive tumor characteristic.
Journal ArticleDOI
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
Hans Petter Eikesdal,Hans Petter Eikesdal,Synnøve Yndestad,Synnøve Yndestad,Asmaa Elzawahry,Asmaa Elzawahry,Alba Llop-Guevara,Bjørnar Gilje,Egil S. Blix,Helge Espelid,Steinar Lundgren,Jürgen Geisler,Jürgen Geisler,Geirfinn Vagstad,Andreas Venizelos,Andreas Venizelos,Laura Minsaas,Laura Minsaas,Beryl Leirvaag,Beryl Leirvaag,Einar Gudlaugsson,Olav Karsten Vintermyr,Olav Karsten Vintermyr,Hildegunn Siv Aase,Turid Aas,Judith Balmaña,Violeta Serra,Emiel A. M. Janssen,Stian Knappskog,Stian Knappskog,Per Eystein Lønning,Per Eystein Lønning +31 more
TL;DR: Olaparib yielded a high clinical response rate in treatment-naïve TNBCs revealing HR deficiency, beyond germline HR mutations, and in contrast to BRCAness signature or basal-like subtype, low RAD51 scores, high TIL or high PD-L1 expression all correlated to olaparIB response.
Journal ArticleDOI
BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.
Hildegunn Høberg-Vetti,Cathrine Bjorvatn,Cathrine Bjorvatn,Bent Fiane,Turid Aas,Kathrine Woie,Helge Espelid,Tone Rusken,Hans Petter Eikesdal,Hans Petter Eikesdal,Wenche Listøl,Marianne Tveit Haavind,Per M. Knappskog,Per M. Knappskog,Bjørn Ivar Haukanes,Vidar M. Steen,Vidar M. Steen,Nicoline Hoogerbrugge,Nicoline Hoogerbrugge +18 more
TL;DR: The results of the DNA-BONus study show that BRCA1/2 testing is well accepted in newly diagnosed breast and ovarian cancer patients, and current test criteria based on age and family history are sufficient to identify most BRCa1/ 2 mutation carriers among breast cancer patients.